Heinrich K, Modest DP, Ricard I, Fischer von Weikersthal L, et al. Gender-dependent survival benefit from first-line irinotecan in metastatic
colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study,
AIO-KRK-0110). Eur J Cancer 2021;147:128-139.
PMID: 33647548